Rafael Holdings, Inc. Class B
As of Oct 22, 2026, Rafael Holdings is in Stage 3, the topping phase, now in week 7 (since Sep 10, 2026). It closed at $1.28, 66.1% below its 52-week high and below its 200-day average, which is rising.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RFL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RFL among Real Estate Services15th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | RMR | Stage 3 · wk 8 | 79 | −3.1% |
| 2 | COMP | Stage 3 · wk 5 | 77 | +8.8% |
| 3 | IHS | Stage 2 · wk 43 | 75 | +0.4% |
| 4 | IRS | Stage 4 · wk 9 | 72 | −6.0% |
| 5 | PETZ | Stage 2 · wk 5 | 72 | −3.0% |
| 6 | HBNB | Stage 4 · wk 19 | 71 | −2.8% |
| 7 | CHCI | Stage 2 · wk 9 | 70 | −12.2% |
| 8 | TCI | Stage 2 · wk 1 | 65 | +17.4% |
| …15 | RFL | Stage 3 · wk 7 | 48 | −36.6% |
Rafael Holdings: quick answers
What stage is Rafael Holdings in?
As of Oct 22, 2026, Rafael Holdings (RFL) is in Stage 3, the topping phase. It entered Stage 3 on Sep 10, 2026 and is in week 7. What the four stages mean
Is Rafael Holdings in an uptrend?
Its uptrend has stalled. Rafael Holdings is in Stage 3, the topping phase that follows an advance. It trades 23.9% below its 200-day average, which is rising.
How far is Rafael Holdings from its 52-week high?
Rafael Holdings closed at $1.28 on Oct 22, 2026, 66.1% below its 52-week high of $3.78. Its 52-week low is $1.16.
How has Rafael Holdings performed over the past year?
As of Oct 22, 2026, Rafael Holdings is down 7.2% over the past year and up 1.6% so far in 2026.
Which sector and industry is Rafael Holdings in?
Rafael Holdings is in the Real Estate Services industry, part of the Real Estate sector.
About this companyReal Estate· Real Estate Services
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.